BMS-986299 | NLRP3 agonist

CAS:
 2242952-69-6
Catalog Number:
 10-4419
BMS-986299 chemical structure

Available Options

Size:PriceQuantity 
5 mg$100.00
25 mg$350.00
Request Quote / Bulk / Custom Size
Product Inquiry

BMS-986299 (2242952-69-6) is a first-in-class NLRP3 inflammasome agonist, active in humans and mice.1 It induced IL-1ß with EC50 = 0.5 µM in human PBMCs. Alone or with checkpoint blockage (anti-PD-1 or anti-CTLA-4), BMS-986299 displayed significant antitumor activity via innate immune system activation in mouse syngeneic tumor models. It significantly promoted T-cell infiltration into the tumor microenvironment and displayed antitumor activity alone and in combination with nivolumab or ipilimumab in a phase 1 study of patients with various advanced solid tumors.2

References/Citations:

  1. Burke et al. (2018) Preclinical characterization of BMS-986299, a first-in-class NLRP3 innate agonist with potent antitumor activity, alone and in combination with checkpoint blockade; J.  Immunother. Cancer. 6 Suppl 1 P524
  2. Nelson et al. (2025) Phase I study of BMS-986299, an NRLP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors; J. Immunother. Cancer. 13 e010013
2242952-69-6, BMS-986299, BMS-986299 supplier, BMS986299, NLRP3 agonist
CAS:
2242952-69-6
Catalog Number:
10-4419
Activity:
NLRP3 agonist
Chemical Names:
N-[[4-Amino-7-(1H-pyrazol-5-yl)-3H-imidazo[4,5-c]quinolin-2-yl]methyl]-N-ethylacetamide
Molecular Weight:
349.40
Molecular Formula:

C18H19N7O

Solubility:
Soluble in DMSO (20 mg/ml)
Physical Properties:
White solid
Purity:

99% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

BMS-986299 (2242952-69-6) is a first-in-class NLRP3 inflammasome agonist, active in humans and mice.1 It induced IL-1ß with EC50 = 0.5 µM in human PBMCs. Alone or with checkpoint blockage (anti-PD-1 or anti-CTLA-4), BMS-986299 displayed significant antitumor activity via innate immune system activation in mouse syngeneic tumor models. It significantly promoted T-cell infiltration into the tumor microenvironment and displayed antitumor activity alone and in combination with nivolumab or ipilimumab in a phase 1 study of patients with various advanced solid tumors.2

References/Citations:

  1. Burke et al. (2018) Preclinical characterization of BMS-986299, a first-in-class NLRP3 innate agonist with potent antitumor activity, alone and in combination with checkpoint blockade; J.  Immunother. Cancer. 6 Suppl 1 P524
  2. Nelson et al. (2025) Phase I study of BMS-986299, an NRLP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors; J. Immunother. Cancer. 13 e010013

STEM CELL

BOGO